ZUG, SWITZERLAND – CRISPR Therapeutics, a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today, June 25, announced it is building a new cell therapy manufacturing facility in Framingham, for clinical and commercial production of the Company’s investigational cell therapy product candidates.
The company did not answer questions SOURCE asked about the construction costs and timelines, and instead just referred the media outlet to its press release.
“We look forward to building a state-of-the-art manufacturing facility, which will accelerate our programs and allow us to scale for commercial supply. We are thankful for the support from the City of Framingham and the Commonwealth of Massachusetts, and we look forward to bringing our facility online rapidly,” said Samarth Kulkarni, Ph.D., Chief Executive Officer of CRISPR Therapeutics. “In addition to building out this internal manufacturing capacity, we will continue to work closely with our key manufacturing partners globally.”
As the facility becomes fully operational, the Company expects to hire up to approximately 100 full-time employees.
The new facility is being designed to provide GMP manufacturing according to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) regulations and guidelines to support clinical supply and commercial product upon potential regulatory approval.